

CB2 Insights Inc.

11:18 03 Dec 2019

Buds & Duds: Marijuana stocks mixed at open; CB2 Insights heads higher on new medical cannabis partnership

Cannabis stocks were a mixed bag on Tuesday across North American markets.

The North American Marijuana Index, which tracks the top cannabis stocks in the US and Canada, fell 1.2% at 113 points. Elsewhere, the Horizons Marijuana Life Sciences Index ETF was up 0.9% at C\$9.11, while the OTCQX Cannabis dropped 1.8% at 435.1 points.

Buds

CB2 Insights Inc (CSE:CBII) (OTCQB:CBIIF) shares rose on Tuesday after the data company revealed it is partnering with licensed producer FCM Global S.A.S, the first Colombian cannabis company to be fully licensed in cultivation, manufacturing and export of low-THC cannabis extracts, to support medical cannabis research and clinical trials.

In a statement, the Toronto-based company said the partnership will work to create market access and design clinical trials to support the deployment of future FCM cannabinoid-based products.

CB2's shares gained 33.5% over the counter at US\$0.14 and 3.7% in Canada to stand at C\$0.14.

Charlotte's Web Holdings Inc (TSE:CWEB) (OTCMKTS:CWBHF) found itself in the green upon the closing of a C\$66.3 million financing to fund the hemp CBD extracts company's business development efforts.

The Boulder-based company's shares rose 3.1% in Toronto at C\$12.20 and 3.7% over the counter to hit US\$9.22.

Elsewhere, Aurora Cannabis Inc (TSE:ACB) (NYSE:ACB) shares rose 3.1% in Toronto at C\$3.32 and 3.7% in New York at US\$2.53 after it received one of the first medical cannabis approvals in Ireland for its High CBD oil drops.

Duds

Harvest Health & Recreation Inc (CSE:HARV) (OTCMKTS:HRVSF) dropped 3.4% in Canada at C\$3.14 and 2.9% on OTC markets at US\$2.38 following a board reshuffle that saw the US cannabis company appoint two new members on Tuesday.

Cresco Labs Inc (CSE:CL) (OTCMKTS:CRLBF) sank 5.5% at C\$6.68 and 5.6% over the counter at US\$5.03 after unveiling a new at-the-market offering of C\$55 million. The offering will see the cannabis company sell subordinate voting shares on the Canadian Securities Exchange to generate cash for its operations.

Contact Angela at angela@proactiveinvestors.com

Follow her on Twitter @AHarmantas

Price: 0.075

Market Cap: \$6 m

1 Year Share Price Graph



April 2019 September 2019 March 2020

Share Information

Code: CBII

Listing: CSE

52 week	High	Low
	0.335	0.055

Sector: Cannabis

Website: cb2insights.com

Company Synopsis:

Our mission is to deliver the industry's most comprehensive, data-driven software and services - transforming the way the global cannabis industry evolves through actionable insights.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of CB2 Insights Inc. named herein, including the promotion by the Company of CB2 Insights Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).